- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Surrozen Inc(SRZN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SRZN
11/20/2026: SRZN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Surrozen Inc is a clinical-stage biotechnology company focused on discovering and developing antibody therapeutics that selectively modulate the Wnt pathway for tissue repair. The company's primary strength lies in its innovative scientific platform and specialized pipeline targeting high-value ophthalmic and vascular conditions like diabetic macular edema. Its main investment opportunity centers on potential clinical breakthroughs from lead candidates such as SZN-8141. However, the company faces notable financial risks, including zero commercial product revenue, high cash burn, and typical clinical-stage development uncertainties. Surrozen best suits risk-tolerant growth investors who closely monitor clinical trial readouts and regulatory updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Offers high potential upside tied to clinical data readouts, but lacks steady commercial growth metrics. |
| Momentum investor | Strong fit while signal remains positive | Can experience sharp price movements and volume surges around clinical trial updates and biotech sector catalysts. |
| Value investor | Weak fit | The company lacks traditional earnings, profitability, or asset-backed valuation safety margins. |
| Dividend investor | Weak fit | Surrozen pays no dividends and retains all capital for clinical pipeline development. |
| Low-risk investor | Weak fit | Early-stage biotechnology investing entails high binary clinical and market volatility risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks frequently experience dramatic price swings based on trial announcements. |
| Valuation risk | High | Valuations are driven by future clinical expectations rather than current earnings or cash flows. |
| Competition risk (biotech therapeutic alternatives) | Medium / high | Alternative treatments developed by well-funded peers can threaten the commercial viability of pipeline assets. |
| Business quality | Medium | The firm has innovative scientific foundations but lacks a diversified commercial revenue base. |
| Dividend income | Low / none | No dividend distributions are made or anticipated in the near term. |
| Execution risk | High | Success relies heavily on executing complex clinical trials and securing regulatory clearances. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 642.73M USD | Price to earnings Ratio - | 1Y Target Price 63.5 |
Price to earnings Ratio - | 1Y Target Price 63.5 | ||
Volume (30-day avg) 343.2K shares | Beta 0.56 | 52 Weeks Range 12.79 - 37.83 | Updated Date 11/20/2026 |
52 Weeks Range 12.79 - 37.83 | Updated Date 11/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -41.94 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.2%
- Active BUY / eligible
- 19 / 44
- 30-Day BUY Count Change
- +12
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -62.76% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and License Agreements | Upfront payments, research funding, and development milestones from major pharmaceutical partners. | Revenue is currently episodic and dependent on partnership milestones rather than commercial product sales. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 488.58M | Price to Sales(TTM) 61.05 |
Enterprise Value 488.58M | Price to Sales(TTM) 61.05 | ||
Enterprise Value to Revenue 48.49 | Enterprise Value to EBITDA 0.71 | Shares Outstanding 20.96M | Shares Floating 13.51M |
Shares Outstanding 20.96M | Shares Floating 13.51M | ||
Percent Insiders 1.76 | Percent Institutions 83.63 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

